- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05093634
EMANATE: MC4R 경로에 특정 유전자 변이가 있는 환자의 Setmelanotide에 대한 연구
3상, 무작위, 이중 맹검, 위약 대조 시험: 멜라노코르틴-4 수용체 경로에 POMC/PCSK1, LEPR, NCOA1(SRC1) 또는 SH2B1 유전자 변이가 있는 환자를 대상으로 한 세트멜라노타이드의 다중 독립 하위 연구
The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in participants with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway:
- Pro-opiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1; Sub-study 035a)
- Leptin receptor (LEPR; Sub-study 035b)
- Nuclear receptor coactivator 1 (NCOA1; steroid receptor coactivator 1 [SCR1]; Sub-study 035c)
- Steroid receptor coactivator-1 homology 2 B adapter protein 1 (SH2B1; Sub-study 035d)
The objectives and endpoints are identical for these sub-studies.
연구 개요
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Rio, 그리스, 26504
- University of Patras School of Medicine
-
-
-
-
-
Rotterdam, 네덜란드, 3015 GD
- Erasmus Medisch Centrum
-
-
-
-
-
Berlin, 독일, 10117
- Charite - Universitatsmedizin Berlin
-
Frankfurt, 독일, 60596
- Endokrinologikum Frankfurt
-
Leipzig, 독일, 04103
- Universitaetsklinikum Leipzig
-
Ulm, 독일, 89075
- Universitaetsklinikum Ulm
-
-
-
-
Arizona
-
Phoenix, Arizona, 미국, 85016
- Phoenix Children's Hospital
-
Scottsdale, Arizona, 미국, 85258
- HonorHealth Bariatric Center
-
-
California
-
Los Angeles, California, 미국, 90027
- Children's Hospital Los Angeles
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- Children's Hospital Colorado
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06519
- Yale Center for Clinical Investigation
-
-
Florida
-
Altamonte Springs, Florida, 미국, 32701
- Advent Health
-
Gainesville, Florida, 미국, 32610
- University of Florida
-
-
Georgia
-
Suwanee, Georgia, 미국, 30024
- InQuest Medical Research
-
-
Massachusetts
-
Worcester, Massachusetts, 미국, 01655
- UMASS Memorial Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48105
- University of Michigan
-
Dearborn, Michigan, 미국, 48126-2619
- Metro Detroit Endocrinology Center
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55902
- Mayo Clinic
-
-
Mississippi
-
Madison, Mississippi, 미국, 39110
- Mississippi Center for Advanced Medicine
-
-
Missouri
-
Chesterfield, Missouri, 미국, 63017
- St. Luke's Hospital
-
Kansas City, Missouri, 미국, 64108
- Children's Mercy
-
St Louis, Missouri, 미국, 63130
- Washington University in St. Louis
-
-
New York
-
Buffalo, New York, 미국, 14260
- University of Buffalo
-
New York, New York, 미국, 10032
- Columbia University
-
New York, New York, 미국, 10029
- Mount Sinai Hospital
-
New York, New York, 미국, 10029
- Metropolitan Hospital Center
-
Staten Island, New York, 미국, 10306
- Ten's Medical Center - Pediatric Endocrinology Clinic
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, 미국, 44195
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Danville, Pennsylvania, 미국, 17822
- Geisinger Clinic
-
Philadelphia, Pennsylvania, 미국, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, 미국, 15213
- UPMC Montefiore
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37232
- Vanderbilt University School of Medicine
-
-
Texas
-
Amarillo, Texas, 미국, 79106
- Texas Tech
-
Houston, Texas, 미국, 77030
- Texas Children's Hospital
-
Houston, Texas, 미국, 77084
- Biopharma Informatic
-
McAllen, Texas, 미국, 78503
- Rio Grande Valley Endocrine Center
-
Plano, Texas, 미국, 75093
- Endocrine Associates of Dallas and Plano
-
-
Washington
-
Tacoma, Washington, 미국, 98405
- MultiCare Health System Institute for Research and Innovation
-
-
West Virginia
-
Morgantown, West Virginia, 미국, 26506
- West Virginia University
-
-
Wisconsin
-
Marshfield, Wisconsin, 미국, 54449
- Marshfield Clinic Research Foundation, a Division of Marshfield Clinic, Inc
-
-
-
-
-
Barcelona, 스페인, 08950
- Hospital Sant Joan de Deu, Barcelona
-
Cadiz, 스페인
- Puerta del Mar University Hospital
-
Madrid, 스페인, 28040
- Hospital Fundación Jimenez Díaz
-
Málaga, 스페인, 29010
- Hospital Universitario Virgen de la Victoria de Málaga
-
Valencia, 스페인, 46014
- Hospital General de Valencia
-
-
-
-
-
Bristol, 영국, BS2 8AE
- Bristol Royal Hospital for Children
-
Cambridge, 영국, CB2 0QQ
- University of Cambridge
-
Liverpool, 영국, L9 7AL
- Aintree University Hospital
-
London, 영국, W2 1NY
- Imperial College Healthcare Trust
-
London, 영국, NW1 2PG
- London Medical - The London Diabetes Centre
-
London, 영국, WC1E6JF
- University College London Hospitals NHS Foundation Trust
-
Manchester, 영국, M13 9WL
- Manchester Children's Hospital
-
-
-
-
-
Petah Tikva, 이스라엘, 49372
- Hasharon Hospital
-
Ramat Gan, 이스라엘, 52621
- Chaim Sheba MC, Safra Children's Hospital
-
-
-
-
Alberta
-
Edmonton, Alberta, 캐나다, T6G 2E1
- University of Alberta - Alberta Diabetes Institute (ADI)
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
San Juan, 푸에르토 리코, 00925-253
- University of Puerto Rico
-
San Juan, 푸에르토 리코, 00927
- Puerto Rico Consortium for Clinical Investigation, Inc.
-
-
-
-
-
Lyon, 프랑스, 69677
- GH Est Hopital Femme Mere Enfant
-
Paris, 프랑스, 75651
- Hu Pitie Salpetriere Aphp
-
Paris, 프랑스, 75771
- Hopital Armand Trousseau
-
Pessac, 프랑스, 33604
- Centre Hospitalier Universitaire (CHU) de Bordeaux
-
Saint-Denis, 프랑스, 97400
- Hôpital Félix Guyon Bellepierre
-
Toulouse, 프랑스
- CHU de Toulouse Hopital des Enfants
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Participants must have a pre-identified:
- Heterozygous genetic variant in the POMC gene or PCSK1 gene
- Heterozygous genetic variant in the LEPR gene
- Homozygous, heterozygous, or compound heterozygous variant in the NCOA1 (SRC1)
- Homozygous, heterozygous, or compound heterozygous variant in SH2B1 gene, or chromosomal 16p11.2 deletion encompassing the SH2B1 gene
-
Between 6 and 65 years of age at the time of provision of informed consent/assent
-
Obesity, defined as body mass index (BMI) ≥30 kg/m^2 for participants ≥18 years of age or BMI ≥95th percentile for age and gender for participants 6 up to 17 years of age
-
Participant and/or parent or guardian is able to understand and comply with the requirements of the study and is able to understand and sign the written informed consent/assent
-
Participant and/or parent or guardian reports that participant experienced childhood obesity, defined as the participant and/or parent or guardian reporting that the participant had obesity or was significantly overweight during childhood
-
Agree to use a highly effective form of contraception throughout the study and for 90 days following the study
-
Reported history of lifestyle intervention of diet and exercise
-
Symptoms or behaviors of hyperphagia persistent during the participant's life, including manifestations in childhood, as determined by the Investigator at screening.
Key Exclusion Criteria:
- Weight loss of 2% or greater in the previous 3 months
- Bariatric surgery or procedure within the previous 6 months
- Significant psychiatric disorder(s)
- Suicidal ideation, attempt or behavior
- Clinically significant pulmonary, cardiac, endocrine/metabolic, hepatic or oncologic disease
- Glycated hemoglobin (HbA1C) >10% at Screening
- History of significant liver disease or severe kidney disease
- History or close family history (parents or siblings) of melanoma, or participant history of oculocutaneous albinism
- Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)
- Participation in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing
- Previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide
- Significant hypersensitivity to any excipient in the study drug
- If female, pregnant or breastfeeding
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: POMC or PCSK1 variant
1:1 Randomization |
Subcutaneous Injection Subcutaneous Injection |
|
실험적: LEPR variant
1:1 Randomization |
Subcutaneous Injection Subcutaneous Injection |
|
실험적: NCOA1 (SRC1) variant
1:1 Randomization |
Subcutaneous Injection Subcutaneous Injection |
|
실험적: SH2B1 variant
1:1 Randomization |
Subcutaneous Injection Subcutaneous Injection |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Treatment Period: Percent Change From Baseline in Body Mass Index (BMI)
기간: Baseline, Week 52
|
BMI was calculated using participant's weight and height assessments as weight in kilograms (kg)/(height in meters [m])^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration. An analysis of covariance (ANCOVA) model was used to calculate the least-squares mean with randomization stratification factors and baseline value as a covariate. |
Baseline, Week 52
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Treatment Period: Percentage of Participants Who Achieved at Least a 5% Reduction in Baseline BMI
기간: Baseline, Week 52
|
BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration. |
Baseline, Week 52
|
|
Treatment Period (Participants Aged ≥18 Years): Percent Change From Baseline in Body Weight
기간: Baseline, Week 52
|
Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration |
Baseline, Week 52
|
|
Treatment Period (Participants Aged ≥12 Years): Percent Change From Baseline in Weekly Average Most Hunger Score
기간: Baseline, Week 52
|
Participants ≥12 years of age who were able to validly and reliably self-report were administered "Hunger Questions for Participants ≥12 Years of Age©." The 'most hunger' item was designed to be evaluated separately and was averaged on a weekly basis. Participants were asked 'In the last 24 hours, how hungry did you feel when you were the most hungry?' and rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all and 10 = hungriest possible). Data reported are for mean percent change from baseline in the weekly average daily most hunger score. Baseline was defined as the last available measurement taken prior to the start of treatment administration. |
Baseline, Week 52
|
|
Treatment Period: Percentage of Participants Who Achieved at Least a 10% Reduction in Baseline BMI
기간: Baseline, Week 52
|
BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration. |
Baseline, Week 52
|
|
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI Z-score
기간: Baseline, Week 52
|
BMI z-scores were calculated according to the Centers for Disease Control and Prevention (CDC) Growth Charts and according to participant's gender and age at screening. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease in BMI Z-score (< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (> 0) indicated an increase in BMI from Baseline. Data reported are for mean percent change from baseline in BMI Z-score. Baseline was defined as the last available measurement taken prior to the start of treatment administration. |
Baseline, Week 52
|
|
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI 95th Percentile
기간: Baseline, Week 52
|
The percentage change from baseline in BMI 95th percentile was calculated as ([BMI at Week 52 / BMI 95th percentile]) - [BMI at baseline / BMI 95th percentile])*100. BMI percentile scores are measures of relative weight adjusted for child age and gender. The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population. Data reported are for mean percent change from baseline in BMI 95th percentile. Baseline was defined as the most recent measurement prior to the first administration of study drug. |
Baseline, Week 52
|
|
Treatment Period: Percent Change From Baseline in Waist Circumference
기간: Baseline, Week 52
|
The waist circumference (in centimeters [cm]) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. Data reported are for mean percent change from baseline in waist circumference. Baseline was defined as the last available measurement taken prior to the start of treatment administration. |
Baseline, Week 52
|
|
Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
기간: Baseline up to 60 weeks
|
TEAEs were defined as any untoward medical occurrence temporally associated with the use of study treatment, whether or not considered related to the study treatment that happened on or after the date of the first study treatment administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. |
Baseline up to 60 weeks
|
|
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Physical Functioning Score on the Impact of Weight on Quality of Life (IWQOL)-Lite
기간: Baseline, Week 52
|
The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire. The physical function domain comprised 11 items which had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The score of each item was summed to calculate the raw score. The raw score range of the physical function domain was 11-55 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in physical functioning score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration. |
Baseline, Week 52
|
|
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy
기간: Baseline, Week 52
|
The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire. The physical comfort domain comprised 6 items which used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw score. The raw score range of the physical function domain was 6-30 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration. |
Baseline, Week 52
|
|
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Lite
기간: Baseline, Week 52
|
The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire which comprised of 5 domains (physical function, self-esteem, sexual life, distress and work) and had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The items were summed to calculate the raw total score. The raw total score range was 31-155 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration. |
Baseline, Week 52
|
|
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy
기간: Baseline, Week 52
|
The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire and comprised of 4 domains (physical comfort, body esteem, social life, family relations) and used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw total score. The raw total score range was 27 to 135 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration. |
Baseline, Week 52
|
|
Treatment Period: Percent Change From Baseline in Body Weight in Setmelanotide Initial Responders Versus Placebo
기간: Baseline, Week 52
|
Initial responders were defined as setmelanotide treated participants with ≥5% body weight loss (≥18 years of age) or a decrease in BMI by ≥3% (<18 years of age) at the time of consecutive 12 weeks with the increased 3.0 mg/day or with final increased dose level. Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration. |
Baseline, Week 52
|
공동 작업자 및 조사자
수사관
- 연구 의자: David Meeker, MD, Rhythm Pharmaceuticals, Inc.
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- RM-493-035
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .